Verisante Technology Inc (VRS.H)

[hongkongwalt88888888]

reposted from another Verisante discussion Forum

the battle will be won by the biopsy ratios

doctors 200:1 for all cancerous lesions cited by Verisante (200 biopsies for every 1 skin cancer diagnosis)

dermatologists 50:1 for melanoma cited by Mela Sciences

VERISANTE AURA - 1.03:1 - so this means 1.03 biopsies for every real cancer diagnosis - people this is stunning!

MELA FIND: 7.6:1 -7.6 Biopsies for every 1 successful melanoma diagnosis

PEOPLE - think about this; the study for Verisante's AURA still has not been published by the scientific journal - the company has to be very careful as to what they say publicly until this paper is published as saying anything or promoting the results of the paper prior to the specific scientific journals publication would be in direct violation of the publication agreement and would directly threaten the process. Go ahead and call the company to verify this.

Early investors are very lucky that Professor Zeng was invited for the SPIE conference in January -giving us a tiny peek into the (in my opinion) stellar results of this study.

In my best guess - once this longly anticipated paper is published - company promotion will be through the roof - think about it.

Everything to me seems ready to go - it is just the formalities of publishing a peer-reviewed scientific paper - an antiquated and slow process that needs to be this way - it just doesn't bode well for impatient investors.

tick tick tick....we are getting closer.

What will Verisante's biopsy ratio be for melanoma?

How were the statistic's calculated and how does this compare to the Melafind study?

Only my well researched thoughts. Please do your own due diligence.

--my thoughts--
While observing the SPIE presentation, that was one of those moments where it clicked for me. The biopsy ratios really highlighted a marked improvement over the past methods of skin cancer diagnosis. I wait anxiously for the next report on FDA status. = ] hkwalt